doi:10.3969/j.issn.1004-583X.2023.06.018

Abstract

CLC Number:

R541.6

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.06.018

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I6/573

References 30

[1]	Yamamoto S, Yamamoto M, Nakamura J, et al. Spatiotemporal ATP dynamics during AKI predict renal prognosis[J]. J Am Soc Nephrol, 2020, 31(12):2855-2869. doi: 10.1681/ASN.2020050580 pmid: 33046532
[2]	Krychtiuk KA, Kaun C, Hohensinner PJ, et al. Anti-thrombotic and pro-fibrinolytic effects of levosimendan in human endothelial cells in vitro[J]. Vascul Pharmacol, 2017, 90:44-50. doi: 10.1016/j.vph.2017.02.003 URL
[3]	潘莉, 陈旭红. 左西孟旦对右心室衰竭大鼠右心功能、心肌能量代谢和心肌代谢的影响[J]. 中国医院药学杂志, 2018, 38(15):1590-1594.
[4]	Lyhne MD, Dragsbaek SJ, Hansen JV, et al. Levosimendan, milrinone, and dobutamine in experimental acute pulmonary embolism[J]. Pulm Circ, 2021, 11(3):20458940211022977.
[5]	汪雁博, 郝国贞, 姜云发, 等. 左西孟旦对急性失代偿性心力衰竭患者右心功能的影响研究[J]. 中国全科医学, 2019, 22(27):3328-3332. doi: 10.12114/j.issn.1007-9572.2019.00.301
[6]	赵文思. 左西孟旦对右心功能的影响[D]. 湖南: 南华大学, 2020.
[7]	Abdelrahman AM, AI Salam S, AI Sulemani Y, et al. Effect of levosimendan, an inodilator, on streptozotocin-induced diabetic nephropathy in rats[J]. Eur J Pharmacol, 2020, 873:172960. doi: 10.1016/j.ejphar.2020.172960 URL
[8]	Tian L, Wang S, Zhao L, et al. Renoprotective effects of levosimendan on acute kidney injury following cardiac arrest via anti-inflammation, anti-apoptosis and ERK activation[J]. FEBS Open Bio, 2021, 11(8):2236-2244. doi: 10.1002/2211-5463.13227 pmid: 34115930
[9]	Guerrero-Orriach JL, Malo-Manso A, Ramirez-Aliaga M, et al. Renal and neurologic benefit of levosimendan vs dobutamine in patients with low cardiac output syndrome after cardiac surgery: Clinical trial FIM-BGC-2014-01[J]. Front Pharmacol, 2020, 11:1331. doi: 10.3389/fphar.2020.01331 pmid: 32982742
[10]	周程辉, 龚俊松, 刘斌. 左西孟旦对左心功能不全心脏病患者围术期肾保护作用的系统评价与Meta分析[J]. 中国胸心血管外科临床杂志, 2019, 26(5):470-479.
[11]	魏望江, 曾志立, 吴其明. 左西孟旦对心力衰竭患者心肾功能影响的meta分析[J]. 世界临床药物, 2021, 42(3):181-187.
[12]	Long YX, Cui DY, Kuang X, et al. Effect of levosimendan on renal function in background of left ventricular dysfunction: A meta-analysis of randomized trials[J]. Expert Opin Drug Saf, 2021, 20(11) : 1411-1420. doi: 10.1080/14740338.2021.1951700 URL
[13]	Hein M, Zoremba N, Bleilevens C, et al. Levosimendan limits reperfusion injury in a rat middle cerebral artery occlusion (MCAO) model[J]. BMC Neurol, 2013, 13:106. doi: 10.1186/1471-2377-13-106 pmid: 23937651
[14]	Plaschke K, Bent F, Wagner S, et al. In contrast to its anti-inflammatory and anti-apoptotic peripheral effect, levosimendan failed to induce a long-term neuroprotective effect in a rat model of mild septic encephalopathy: A pilot study[J]. Neurosci Lett, 2014, 560:117-121. doi: 10.1016/j.neulet.2013.12.021 pmid: 24361133
[15]	García-Bardon A, Kamuf J, Ziebart A, et al. Levosimendan increases brain tissue oxygen levels after cardiopulmonary resuscitation independent of cardiac function and cerebral perfusion[J]. Sci Rep, 2021, 11(1): 14220. doi: 10.1038/s41598-021-93621-x pmid: 34244561
[16]	Grossini E, Bellofatto K, Farruggio S, et al. Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay[J]. PLoS One, 2015, 10(4):e0124742. doi: 10.1371/journal.pone.0124742 URL
[17]	Sakaguchi T, Hashimoto Y, Matsushima H, et al. Levosimendan pretreatment improves survival of septic rats after partial hepatectomy and suppresses iNOS induction in cytokine-stimulated hepatocytes.[J]. Sci Rep, 2019, 9(1):13398. doi: 10.1038/s41598-019-48792-z pmid: 31527618
[18]	Grossini E, Pollesello P, Bellofatto K, et al. Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats[J]. Liver Transpl, 2014, 20(3):361-375. doi: 10.1002/lt.23799 URL
[19]	Suakıtıcı S, Güven BB, Tanoglu A, et al. A combination of levosimendan and N-Acetylcysteine shows significant favorable efficacy on experimental liver ischemia/reperfusion injury[J]. Ulus Travma Acil Cerrahi Derg, 2021, 27(4):381-388. doi: 10.14744/tjtes.2020.81782 pmid: 34213003
[20]	杨飞, 王少华, 赵丽娜, 等. 静脉注射左西孟旦治疗晚期严重心力衰竭患者的疗效分析[J]. 中国急救医学, 2018, 38(8):706-710.
[21]	Zemljic G, Anzic DA, Cerar A, et al. Abstract 15719: Levosimendan improves liver function in patients with advanced chronic heart failure[J]. Circulation, 2020, 142(Suppl_3): A15719.
[22]	梅松, 蒋雯, 白向锋, 等. 左西孟旦治疗重症冠心病所致心衰的临床疗效[J]. 昆明医科大学学报, 2021, 42(1):72-75.
[23]	王世伟, 郭建, 杨正飞, 等. 左西孟旦对心肺复苏后大鼠肠道微循环的影响[J]. 临床急诊杂志, 2019, 20(8):612-618.
[24]	Boost KA, Hoegl S, Dolfen A, et al. Inhaled levosimendan reduces mortality and release of proinflammatory mediators in a rat model of experimental ventilator-induced lung injury[J]. Crit Care Med, 2008, 36(6):1873-1879. doi: 10.1097/CCM.0b013e3181743e63 pmid: 18496375
[25]	Gürbüzel M, Sayar I, Cankaya M, et al. The preventive role of levosimendan against bleomycin-induced pulmonary fibrosis in rats[J]. Pharmacol Rep, 2016, 68(2):378-382. doi: 10.1016/j.pharep.2015.10.001 pmid: 26922542
[26]	Fodor GH, Bayat S, Babik B, et al. Reversing cholinergic bronchoconstriction by common inotropic agents: A randomized experimental trial on isolated perfused rat lungs[J]. Anesth Analg, 2019, 129(3):745-752. doi: 10.1213/ANE.0000000000003502 pmid: 31425216
[27]	Rieg AD, Suleiman S, Bünting NA, et al. Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels[J]. PLoS One, 2020, 15(5): e0233176. doi: 10.1371/journal.pone.0233176 URL
[28]	欧伟根, 蔡洪流. 左西孟旦注射液治疗慢性阻塞性肺疾病伴心功能不全的临床研究[J]. 中国临床药理学杂志, 2017, 33(16):1527-1530.
[29]	梅姜. 左西孟旦对困难脱机病人的临床疗效观察[D]. 北京: 北京协和医学院, 2019.
[30]	黄奎, 温小琴, 任宁, 等. 左西孟旦在急性呼吸衰竭合并心力衰竭患者二次脱离机械通气中的应用[J]. 山东医药, 2020, 60(23):48-50.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 30

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(1): 75-79.
[2]	Duan Fang, Cui Wei. Application principles of vasodilators in the treatment of acute heart failure [J]. Clinical Focus, 2023, 38(9): 773-778.
[3]	. [J]. Clinical Focus, 2023, 38(9): 832-837.
[4]	. [J]. Clinical Focus, 2023, 38(5): 459-464.
[5]	Wang Zhen, Yang Xiaoyue, Li Shaojie, Wang Xian, Chen Shuxia, Gu Jian. Analysis of clinical characteristics and readmission risk factors in patients with ejection fraction preserved heart failure combined with atrial fibrillation [J]. Clinical Focus, 2023, 38(4): 308-314.
[6]	. [J]. Clinical Focus, 2023, 38(4): 369-372.
[7]	Zuo Xiuxiu, Hou Tianhua, Wang Hongxiang. Effect of subclinical hypothyroidism on prognosis of patients with chronic systolic heart failure: A meta-analysis [J]. Clinical Focus, 2022, 37(10): 905-911.
[8]	. [J]. Clinical Focus, 2022, 37(9): 838-841.
[9]	Li Heng, Li Yonghui, Sun Xiaoqiang, Wang Lin, He Feng. Efficacy and safety of anticoagulant therapy for patients with heart failure in sinus rhythm [J]. Clinical Focus, 2022, 37(5): 406-411.
[10]	Luo Fanglin, Guan Suying, Wu Guoxiang. Clinical effect of sacubitril-valsartan combined with activin on acute left heart failure [J]. Clinical Focus, 2021, 36(9): 782-785.
[11]	. [J]. Clinical Focus, 2021, 36(7): 641-645.
[12]	Zhao Meili, Xiao Liyuan, Liu Lin, Kang Chao, Zhang Qiuxiang. Correlation between NT-proBNP, hs-CRP, left atrium diameter and chronic heart failure concurrent with atrial fibrillation [J]. Clinical Focus, 2021, 36(5): 412-415.
[13]	Xu Dongrui, Zhao Qinhui, Liu Tongxiang. Clinical effect of sacubitril/valsartan for heart failure with mid-range ejection fraction in left ventricle [J]. Clinical Focus, 2021, 36(5): 416-420.
[14]	Bai Lian, Guo Peng, Luan Bo, Bai Hao, Jiang Shan. Correlation between serum free fatty acid and cardiac function in patients with acute heart failure [J]. Clinical Focus, 2021, 36(3): 208-211.
[15]	. [J]. Clinical Focus, 2020, 35(12): 1126-1131.